Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19)
Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.
COVID-19 TESTING
CLINICAL therapeutics
AXIM’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market
CANCER dIAGNOSTICS
AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer
The Latest On Our Research
What is a COVID-19 “Immunity Passport” and Why is it Better Than a “Vaccine Passport”?
After a little over a year of expedited research, financial hardship and over 500K deaths in the US, we're finally starting to see the light at the end of the COVID-19 tunnel. But while the widespread rollout of vaccines has been encouraging, there are many additional...
What’s a Vaccine Passport and Do You Need One?
Would an “immunity passport” be more effective? The vaccines are still in the early stages of being studied, but they’re thought to be highly effective. However, there are questions that remain. For example, it’s not clear if a vaccinated person who gets the virus can...
AXIM Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test
The Company conducted two studies, one in partnership with the Company’s manufacturing partner Empowered Diagnostics and the second in partnership with a top accredited university medical center. The main goal of these studies was to identify the ability of operators...